# Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

> **NCT00519077** · PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 44 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00519077
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2008-05
- **Final completion:** 2013-05
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2016-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519077, "Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00519077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*